Editas Medicine (STU:8EM) Minority Interest: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8EM Editas Medicine Inc STU:8EM
64 GF Score
Price €2.47
GF Value €2.11
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Editas Medicine Minority Interest?

Editas Medicine STU:8EM +3.78% 64 Minority Interest is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:8EM with a GF Score™ of 64/100 and a GF Value™ of €2.11 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Editas Medicine's minority interest for the quarter that ended in Jun. 2026 was €0.00 Mil.

Editas Medicine Minority Interest Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Editas Medicine Minority Interest Chart

Editas Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Editas Medicine Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:8EM
64GF Score
Editas Medicine Inc STU:8EM
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Editas Medicine Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Editas Medicine (STU:8EM) has a Minority Interest of €0.00 Mil as of Jun. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Editas Medicine.
Is Editas Medicine's Minority Interest too high?
Editas Medicine's current Minority Interest is €0.00 Mil. Overall, Editas Medicine has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's Minority Interest compare to BNTC and PBYI?
Editas Medicine's Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Editas Medicine. Editas Medicine's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (STU:8EM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.11, compared to a current price of €2.47 — trading 17.1% above its estimated fair value. The current Minority Interest is €0.00 Mil. Editas Medicine's overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Editas Medicine (STU:8EM), the current Minority Interest is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (STU:8EM) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of €2.47 is trading 17.1% above its estimated GF Value™ of €2.11. GuruFocus considers Editas Medicine to be Modestly Overvalued.

Key valuation signals for STU:8EM:

  • Minority Interest: €0.00 Mil
  • GF Value™: €2.11 vs. price of €2.47 (17.1% above fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the STU:8EM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges EDIT:USA0IFK:UK
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
64GF Score

Get the complete analysis for STU:8EM

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.47
Price
€2.11
GF Value